Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial

Somayyeh Firouzi, Barakatun-Nisak Mohd-Yusof, Hazreen-Abd Majid, Amin Ismail, Nor-Azmi Kamaruddin, Somayyeh Firouzi, Barakatun-Nisak Mohd-Yusof, Hazreen-Abd Majid, Amin Ismail, Nor-Azmi Kamaruddin

Abstract

Background: The beneficial effect of probiotics on renal profile and liver function has been reported among patients with chronic kidney disease and fatty liver respectively. However, its effect on renal profile and liver function among type 2 diabetic individuals has not been fully understood. To investigate the effect of microbial cell preparation on renal profile and liver function tests among type 2 diabetic individuals.

Methods: A randomized, double-blind, parallel-group, controlled clinical trial was conducted on a total of 136 type 2 diabetics age 30-70 years old in a teaching hospital in Kuala Lumpur, Malaysia. Subjects were randomly assigned to receive microbial cell preparation (N = 68) or a placebo (N = 68) for 12 weeks. The outcomes measured at baseline, week 6, and week 12 and included changes in renal profile (Sodium, Potassium, Urea, Creatinine, Glomerular Filtration Rate), and liver function tests (Albumin, Total Protein, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase). Intention to treat (ITT) analysis was performed on all the recruited subjects, while per protocol (PP) analysis was conducted on those who completed the trial with good compliance.

Result: The urea levels significantly declined in the probiotic group. Serum urea levels reduced from 4.26 mmol/L to 4.04 mmol/L in Probiotic Group while it increased in Placebo Group from 4.03 mmol/L to 4.24 mmol/L. These changes were significant between groups in ITT analysis (p = 0.018). Other parameters did not change significantly between groups.

Conclusion: 12 weeks supplementation with daily dosage of 6 × 10(10) Colony Forming Units of multi-strain microbial cell preparation significantly improved urea levels.

Trial registration: (

Clinical trials: # NCT01752803).

Figures

Fig. 1
Fig. 1
CONSORT flowchart
Fig. 2
Fig. 2
Mean changes in urea levels in Probiotic and Placebo Group over the course of the study
Fig. 3
Fig. 3
Mean urea levels between study groups in week 6 and week 12 among normal weight and OW/OB subjects
Fig. 4
Fig. 4
Comparison of mean changes in Urea levels between study groups according to their baseline value

References

    1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. J Am Soc Nephrol. 2013;24:302–308. doi: 10.1681/ASN.2012070718.
    1. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734–743. doi: 10.2337/dc06-1539.
    1. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2012;83:308–315. doi: 10.1038/ki.2012.345.
    1. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887. doi: 10.1002/hep.22848.
    1. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant. 2011;26:1094–1098. doi: 10.1093/ndt/gfq624.
    1. Simenhoff ML, Dunn SR, Zollner GP, Fitzpatrick ME, Emery SM, Sandine WE, et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab. 1996;22:92.
    1. Alatriste PVM, Arronte RU, Espinosa COG. Cuevas M d LÁE: Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014;29:582–590.
    1. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther. 2010;27:634–647. doi: 10.1007/s12325-010-0059-9.
    1. Ma YY, Li L, Yu C-H, Shen Z, Chen L-H, Li Y-M. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol WJG. 2013;19:6911. doi: 10.3748/wjg.v19.i40.6911.
    1. Rishi P, Mavi SK, Bharrhan S, Shukla G, Tewari R. Protective efficacy of probiotic alone or in conjunction with a prebiotic in Salmonella-induced liver damage. FEMS Microbiol Ecol. 2009;69:222–230. doi: 10.1111/j.1574-6941.2009.00703.x.
    1. Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. Chichester: Wiley; 1990.
    1. Cole HS, Camerini-Davalos RA. Diet therapy of diabetes mellitus. Med Clin North Am. 1970;54:1577–1587.
    1. Malaysian Dietitians’ Association. Medical Nutrition Therapy Guideline for Type 2 Diabetes Mellitus. Ministry of Health, Kuala Lumpur; Malaysia 2013.
    1. Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc. 2003;43:668–679. doi: 10.1331/154434503322642598.
    1. WHO: Obesity. Preventing and Managing the Global Epidemic Report of a WHO Consultation (WHO Technical Report Series 894). World Health Organization; Geneva 2000.
    1. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sport Exerc. 2003;35:1381.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
    1. Fritz C, Morris P, Richler J. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2–18. doi: 10.1037/a0024338.
    1. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006;104:c20–c27. doi: 10.1159/000093255.
    1. Goldring W, Razinsky L, Greenblatt M, Cohen S. The influence of protein intake on the urea clearance in normal man. J Clin Invest. 1934;13(5):743–748. doi: 10.1172/JCI100617.
    1. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens. 2012;21:587–592. doi: 10.1097/MNH.0b013e328358c8d5.
    1. Parvez S, Malik KA, Ah Kang S, Kim H-Y. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006;100:1171–1185. doi: 10.1111/j.1365-2672.2006.02963.x.
    1. Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm. 2014;2014:348959. doi: 10.1155/2014/348959.
    1. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis. J Am Coll Nutr. 2003;22:56–63. doi: 10.1080/07315724.2003.10719276.
    1. Fukushima Y, Miyaguchi S, Yamano T, Kaburagi T, Iino H, Ushida K, et al. Improvement of nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented milk containing probiotic Lactobacillus johnsonii La1 (NCC533) Br J Nutr. 2007;98:969–977. doi: 10.1017/S0007114507764723.
    1. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675–682. doi: 10.1016/j.alcohol.2008.08.006.
    1. Wang Y, Kirpich I, Liu Y, Ma Z, Barve S, McClain CJ, et al. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol. 2011;179:2866–2875. doi: 10.1016/j.ajpath.2011.08.039.
    1. Bang CS, Hong SH, Suk KT, Kim JB, Han SH, Sung H, et al. Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhus vernicifera Stokes), and probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut–liver axis of alcoholic liver disease. J Ginseng Res. 2014;38:167–172. doi: 10.1016/j.jgr.2014.04.002.
    1. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008;49:821–830. doi: 10.1016/j.jhep.2008.05.025.
    1. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989–997. doi: 10.1002/hep.22711.
    1. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44–S48. doi: 10.1086/381446.
    1. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res. 2009;39:107–116. doi: 10.1111/j.1872-034X.2008.00441.x.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera